Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
15 studies found for:    siltuximab
Show Display Options
Rank Status Study
1 Active, not recruiting A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
Condition: Multicentric Castleman's Disease
Intervention: Drug: Siltuximab
2 Terminated A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Siltuximab
3 Withdrawn A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Placebo, Velcade and dexamethasone;   Biological: Siltuximab, Velcade and dexamethasone
4 Terminated
Has Results
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab;   Drug: Placebo;   Drug: Best supportive care (BSC)
5 Completed Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Siltuximab;   Drug: Dexamethasone;   Behavioral: Questionnaires
6 Recruiting A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Condition: High-risk Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab;   Drug: Placebo
7 Completed A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Biological: Siltuximab
8 Completed A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Conditions: Ovarian Neoplasms;   Pancreatic Neoplasms;   Colorectal Neoplasms;   Head and Neck Neoplasms;   Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
9 Completed An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Siltuximab;   Drug: Dexamethasone
10 Terminated
Has Results
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Condition: Cancer, Prostate
Interventions: Drug: Mitoxantrone;   Drug: Siltuximab;   Drug: Prednisone
11 Completed
Has Results
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Siltuximab11 mg/kg;   Drug: Siltuximab 8.3 mg/kg or 11 mg/kg;   Drug: Velcade (bortezomib);   Drug: Melphalan;   Drug: Prednisone
12 Active, not recruiting
Has Results
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
Condition: Multicentric Castleman's Disease
Interventions: Drug: Siltuximab;   Drug: Placebo;   Drug: Best Supportive Care (BSC)
13 Completed
Has Results
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Condition: Prostate Cancer
Intervention: Biological: CNTO 328
14 Withdrawn S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Condition: Kidney Cancer
Intervention: Biological: CNTO 328
15 Completed A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants
Condition: Healthy
Interventions: Drug: CNTO 328 (Sp2/0-derived);   Drug: CNTO 328 (CHO-derived);   Drug: Placebo

Indicates status has not been verified in more than two years